Diabetic Retinopathy - Pipeline Insight, 2026

DelveInsight's, "Diabetic Retinopathy - Pipeline Insight, 2026" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Diabetic Retinopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Diabetic Retinopathy: Understanding

Diabetic Retinopathy: Overview

Diabetic retinopathy is a diabetes complication that affects eyes. It is caused by damage to the blood vessels of the light-sensitive tissue at the back of the eye (retina). At first, diabetic retinopathy might cause no symptoms or only mild vision problems. But it can lead to blindness. The condition can develop in anyone who has type 1 or type 2 diabetes. The longer you have diabetes and the less controlled your blood sugar is, the more likely you are to develop this eye complication. The pathophysiology of DR involves a complex interplay of factors such as chronic hyperglycemia, activation of biochemical pathways like the polyol pathway and protein kinase C, increased expression of growth factors such as vascular endothelial growth factor (VEGF), oxidative stress, and inflammation. These mechanisms lead to retinal microvascular damage, neurodegeneration of retinal cells, and structural changes that contribute to vision impairment. Understanding these underlying processes is crucial for the development of effective treatments to prevent and manage diabetic retinopathy. Drops will be put in eye to dilate (widen) the pupil. This allows the ophthalmologist to look through a special lens to see the inside of the eye.

Optical coherence tomography (OCT) to look closely at the retina. A machine scans the retina and provides detailed images of its thickness. This helps your doctor find and measure swelling of your macula. Fluorescein angiography or OCT angiography helps the doctor see what is happening with the blood vessels in the retina. Fluorescein angiography uses a yellow dye called fluorescein, which is injected into a vein (usually in your arm). The dye travels through your blood vessels. A special camera takes photos of the retina as the dye travels throughout its blood vessels. This shows if any blood vessels are blocked or leaking fluid. It also shows if any abnormal blood vessels are growing. OCT angiography is a newer technique and does not need dye to look at the blood vessels.

Controlling blood sugar and blood pressure is essential for preventing vision loss. Following the recommended diet and taking prescribed medications are crucial steps. Medications like Avastin, Eylea, and Lucentis, known as anti-VEGF drugs, are administered through eye injections to reduce macular swelling and improve vision. Steroid injections can also help reduce swelling. Laser surgery can seal leaking blood vessels, reduce retinal swelling, and prevent abnormal blood vessel growth, sometimes requiring multiple treatments. In cases of advanced proliferative diabetic retinopathy (PDR), vitrectomy surgery may be recommended to remove vitreous gel and blood from leaking vessels, allowing light to focus properly on the retina and addressing scar tissue issues.

"Diabetic Retinopathy- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Diabetic Retinopathy pipeline landscape is provided which includes the disease overview and Diabetic Retinopathy treatment guidelines. The assessment part of the report embraces, in depth Diabetic Retinopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Diabetic Retinopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

• The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic Retinopathy R&D. The therapies under development are focused on novel approaches to treat/improve Diabetic Retinopathy.

Diabetic Retinopathy Emerging Drugs Chapters

This segment of the Diabetic Retinopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Diabetic Retinopathy Emerging Drugs

• Tarcocimab tedromer: Kodiak Sciences

Tarcocimab is an investigational anti-VEGF therapy built on Kodiak's proprietary Antibody Biopolymer Conjugate ("ABC") Platform and is designed to maintain potent and effective drug levels in ocular tissues for longer than existing available agents. Kodiak's objective with tarcocimab is to enable earlier treatment and prevention of vision loss for patients with diabetic retinopathy and to develop a new durability agent to improve outcomes for patients with retinal vascular diseases. Currently, the drug is in Phase III stage of its clinical trial for the treatment of diabetic retinopathy.

• VX-01: Vantage Biosciences Ltd

VX-01 is suitable for daily oral chronic dosing to ensure that intraocular concentrations of the drug achieve profound, persistent inhibition of AOC-3 in the neurovascular unit. Previous clinical studies using AOC-3 inhibitors to treat diabetic eye diseases (1,2) were confounded using drug doses that, although effective against soluble AOC-3 circulating in plasma, were insufficient to cross the blood-retina barrier and block AOC-3 in the eye. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Diabetic retinopathy.

• THN391: Therini Bio Pty Ltd

THN391 is an investigational therapy being developed for the treatment of diabetic retinopathy, a progressive microvascular complication of diabetes characterized by retinal inflammation, vascular leakage, and vision impairment. Developed by Therini Bio, THN391 represents a novel approach that targets fibrin-mediated inflammation, an emerging pathological driver in retinal diseases. In diabetic retinopathy, disruption of the blood-retinal barrier leads to the accumulation of fibrin within retinal tissues, which in turn promotes chronic inflammation, microglial activation, and vascular damage. THN391 is designed to selectively neutralize this pathological fibrin activity without interfering with normal blood coagulation, thereby offering a more targeted and potentially safer therapeutic strategy. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diabetic retinopathy.

Diabetic Retinopathy: Therapeutic Assessment

This segment of the report provides insights about the different Diabetic Retinopathy drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Diabetic Retinopathy
• There are approx. 50+ key companies which are developing the therapies for Diabetic Retinopathy. The companies which have their Diabetic Retinopathy drug candidates in the most advanced stage, i.e. Phase III include, Kodiak Sciences.
• Phases

DelveInsight's report covers around 55+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Diabetic Retinopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Diabetic Retinopathy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Diabetic Retinopathy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diabetic Retinopathy drugs.

Diabetic Retinopathy Report Insights

• Diabetic Retinopathy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Diabetic Retinopathy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Diabetic Retinopathy drugs?
• How many Diabetic Retinopathy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diabetic Retinopathy?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Diabetic Retinopathy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Diabetic Retinopathy and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Kodiak Sciences
• RemeGen
• Vantage Biosciences Ltd
• Apexian Pharmaceuticals
• Ocular Therapeutix
• MingSight Pharmaceuticals
• Palatin Technologies
• Regenxbio
• PharmAbcine
• Adverum Biotechnologies
• Therini Bio Pty Ltd

Key Products

• KSI-301
• RC28-E injection
• VX-01
• APX 3330
• OTX-TKI
• MS-553
• PL8177
• RGX 314
• PMC 309
• ADVM-022
• THN391